Time-course based assessment of patient factors and their relationship to chemotherapy induced peripheral neuropathy.

Background: Patients commonly experience chemotherapy-induced peripheral neuropathy (CIPN) as an adverse effect from chemotherapies, such as taxanes. In some patients, CIPN symptoms are severe and significantly impact their quality of life. Gaining a deeper understanding of how patient factors change over time, and identifying predisposing patient factors for CIPN susceptibility, could provide opportunities to mitigate the risk of CIPN and improve patient outcomes. Methods: A total of 229 patients with breast cancer receiving taxane chemotherapy completed study visits over 12 months. Data from patient reported outcomes (PROs) were collected from validated questionnaires to assess CIPN, anxiety, depression, weight, physical function, and sleep disturbance. Wilcoxon signed-rank tests were conducted to evaluate changes in PROs between timepoints (pre-treatment, on-treatment, post-treatment). Logistic regression was used to compare PROs between CIPN and non-CIPN groups at each time point, after adjustment for age, race, and pre-treatment CIPN score. Results were adjusted for multiple comparisons using a false discovery rate (FDR) procedure (FDR Results: Out of 229 patients, 75% developed CIPN. Higher depression scores were associated with CIPN development across the three time periods: pre-treatment (OR = 1.20, FDR Conclusion: These findings indicate that those experiencing CIPN were more likely to report reduced physical functioning, increased anxiety and depression, and have higher BMIs. As new multi-modal approaches are developed for CIPN, pre-treatment physical functioning, BMI and other patient reported measures may provide predictive ability.